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Abstract
Recently, the pathogenic role of uric acid (UA) in both systemic metabolic and atherosclerotic diseases has been investigated. We
sought to determine the independent correlation between serumUA levels and coronary artery calciﬁcation, as amarker of subclinical
atherosclerosis. A total of 4188 individuals without prior coronary artery disease or urate-deposition disease were included. All of the
participants underwent multidetector computed tomography (MDCT) for the evaluation of coronary artery calciﬁcation (CAC) during
their health check-ups. The subjects were divided into thre groups according to CAC scores (group 1: 0; group 2: 1–299; group 3:
≥300). After controlling for other confounders, serum UA levels were found to be positively associated with increasing CAC scores
(P=0.001). Adjustedmean serumUA levels in each CAC groupwere estimated to be 5.2±0.1mg/dL, 5.3±0.1mg/dL, and 5.6±0.2
mg/dL from groups 1, 2, and 3, respectively. Subsequent subgroup analyses revealed that this positive association was only
signiﬁcant in participants who were male, relatively older, less overweight, and did not have diabetes mellitus (DM), hypertension,
smoking history, or renal dysfunction. In conclusion, serum uric acid levels were independently associated with CAC score severity
and this ﬁnding is particularly relevant to the subjects who were male, relatively older, less overweight (body mass index<25kg/m2),
and without a history of DM, hypertension, smoking, or renal dysfunction.
Abbreviations: BMI = body mass index, BUN = blood urea nitrogen, CAC = coronary artery calciﬁcation, CHD = coronary heart
disease, CRP = C-reactive protein, CSF-1 = colony-stimulating factor 1, DM = diabetes mellitus, eGFR = estimated glomerular
ﬁltration rate, HDL= high-density lipoprotein, LDL= low-density lipoprotein, MDCT=multidetector computed tomography, MDRD=
the Modiﬁcation of Diet in Renal Disease, RANKL = receptor activator of NF-kB ligand, TNF-a = tumor necrosis factor-a, UA = uric
acid.
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[1]1. Introduction
Uric acid (UA) is the end product of purine catabolic metabolism.
The serum level of UA is inﬂuenced by multiple factors, including
exogenous ingestion (particularly with an animal protein-richEditor: Giovanni Tarantino.
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1diet), endogenous production by the liver, and renal excretion.
Over the decades, the pathological consequences of excess UA
have been found to be associated with its tendency to form
crystals, as manifested in gouty arthritis or UA stones. This
accumulation triggers complex proinﬂammatory cascades,
leading to increased neutrophil phagocytosis, and activation of
macrophages, ﬁbroblasts, inﬂammatory mediators, and comple-
ment.[2,3] However, more recent evidence suggests that the UA’s
pathological consequences are not conﬁned to local tissue
damage that results from its insoluble, crystallized forms.
Instead, UA can cause a milieu of systemic inﬂammatory
responses that can ultimately cause metabolic and atherosclerotic
diseases. This phenomenon may at least be partially attributable
to the association between hyperuricemia, free radical-induced
oxidative stress, and endothelial dysfunction.[4,5]
A number of epidemiologic studies have indicated that
hyperuricemia itself is closely associated with a wide range of
cardiovascular risk factors such as type 2 diabetes mellitus
(DM),[6] hypertension,[7,8] obesity,[9] incident kidney dis-
ease,[10] and metabolic syndrome.[11] Hyperuricemia has also
been associated with overt cardiovascular events such as
stroke,[12] heart failure,[13] and peripheral artery disease.[14] A
number of studies have also been conducted to investigate the
relationship between hyperuricemia and coronary artery
disease. Particularly in high-risk populations, such as patients
with acute coronary syndrome,[15] metabolic syndrome,[16] or
systolic hypertension,[17] elevated serum UA level is an
Kim et al. Medicine (2017) 96:14 Medicineindependent predictor of poor cardiac outcomes. However, in a
relatively healthy general population, these associations are
insufﬁciently elucidated.
Unstable coronary plaque lesions that are vulnerable to rupture
tend to have focal calcium deposits. Plaque mineralization is
colocalized with various bone morphogenic and proinﬂamma-
tory cytokines.[18] The degree of calciﬁcation, as measured by
multidetector computed tomography (MDCT), is one of the most
widely accepted tools for detecting coronary atherosclerosis and
estimating coronary risk assessment. This tool is also valid in
asymptomatic adults.[19]
Therefore, in this study, we sought to determine whether
serum UA levels are independently associated with the
coronary artery calcium (CAC) scores in the populations
who attended a comprehensive medical check-up course and
free of overt coronary artery disease and urate deposition
disease.2. Methods
2.1. Study population
This was a cross-sectional retrospective single-center study. We
consecutively collected data from 4884 subjects who underwentFigure 1. Flow diagram for participan
2MDCT as part of a routine health check-up between July 2006
and September 2013 at Gangnam Severance Hospital, Yonsei
University College of Medicine, Seoul, South Korea. The
exclusion criteria were as follows: age <20 years or >80 years;
overt coronary artery disease or urate deposition disease
(including gouty arthritis and nephrolithiasis); use of medications
that can affect serum UA level (i.e., diuretics, allopurinol,
febuxostat, colchicine, probenecid, and benzbromarone); and
incomplete medical information. Renal dysfunction was deﬁned
as estimated glomerular ﬁltration rate (eGFR) of <60mL/min/
1.73m2 of the body surface area. A total of 4188 subjects were
ultimately included in the analysis (Fig. 1). This study was
approved by the Institutional Review Board of Gangnam
Severance Hospital, Yonsei University College of Medicine
(IRB no. 3-2015-0128).
2.2. Measurement of clinical and laboratory parameters
Each patient completed a questionnaire to assess smoking status
and previous history of DM, hypertension, gouty arthritis,
nephrolithiasis, or coronary artery disease. Height, body weight,
and blood pressure were measured during the check-up visits.
Blood samples were collected on the day of the MDCT scan after
at least 12hours of fasting. The following laboratory parameters,t screening, eligibility, and analysis.
Kim et al. Medicine (2017) 96:14 www.md-journal.comwhich are potentially associated with coronary risk, were
evaluated: white blood cell count, hemoglobin, C-reactive protein
(CRP), blood urea nitrogen (BUN), creatinine, fasting glucose,
UA, total cholesterol, triglyceride, low-density lipoprotein (LDL)-
cholesterol, and high-density lipoprotein (HDL)-cholesterol.
Kidney function was determined by eGFR, which was based
on the formula developed from the Modiﬁcation of Diet in Renal
Disease (MDRD) study.[20] Body mass index (BMI) was
calculated as body weight (kilograms) divided by the square of
height (square meters).2.3. Multidetector computed tomography (MDCT)
Subjects were scanned using cardiac MDCT (Philips Brilliance
64; Philips Medical Systems, Best, The Netherlands) with a 3mm
slice thickness and 1.5mm reconstruction interval. Cardiac
MDCT was performed in the craniocaudal direction with the
patient in the supine position, during a single breath-hold at the
end-inspiratory suspension. Patients with an initial heart rate
>66beats/min before cardiac MDCT examination received a
b-adrenergic blocker (25mg atenolol; Tenormin, Hyundai,
Seoul, Korea), unless b-blocking agents were contraindicated.
Iodinated contrast (Optiray 350; Tyco Healthcare, Kanata,
Canada) was administered at a dose of 2.0mL/kg (not exceeding
a total of 100 mL) using a two-phase injection protocol for the
arterial and delayed phases of the CT images. Quantitative CACs
were calculated according to the method previously described by
Agatston et al.[21]. Brieﬂy, CAC was determined as a high-
attenuation area in the coronary artery whose attenuation
exceeded the threshold of 130 Hounsﬁeld units in a minimum of
three contiguous pixels.
2.4. Statistical analysis
Continuous variables were compared using an independent t-test
or one-way ANOVA with Bonferroni post-hoc analysis, depend-
ing on the number of groups. ANOVA for linear trend was used
to assess linearity across the groups. Categorical variables were
compared using Pearson’s Chi-square tests with post-hoc analysis
by adjusted residuals. The distribution of CAC scores was highly
skewed (Supplemental Fig. 1, http://links.lww.com/MD/B638).
Therefore, participants were categorized into three groups
according to their CAC scores: CAC group 1 (CAC score: 0,
calcium absent); CAC group 2 (CAC score: 1–299); CAC group 3
(CAC score: ≥300). In contrast, the serum UA level was normally
distributed (Supplemental Fig. 2, http://links.lww.com/MD/
B638). In order to determine if the serum UA levels were
independently associated across the CAC groups, we used linear
regression models by incorporating the serum UA level as a
continuous dependent variable and the CAC groups as the
categorical independent variable. We also included other
confounding baseline parameters as independent factors and
covariates. Other skewed continuous variables were logarithmi-
cally transformed when appropriate. The estimated marginal
means for serum UA levels for each CAC group were calculated,
and pairwise comparisons were tested by using generalized linear
models. The subgroup analysis was performed based on the
categorical variables.
All analyses were performed using SPSS for Windows (version
23.0; SPSS Inc, Chicago, IL) and R version 3.3.2 (http://r-project.
org). All statistical tests were evaluated using a two-tailed 95%
conﬁdence interval. P-values <0.05 were considered statistically
signiﬁcant.33. Results
Baseline characteristics for the subjects by gender are shown in
Table 1. Mean participant age was 53.4±9.7 years and 62.1%
were male. The prevalence of DM, hypertension, and ever
smoking were 7.3%, 20.4%, and 17.2%, respectively. The
average levels of eGFR and serum UA were 94.4±25.7mL/min/
1.73m2 and 5.4±1.4mg/dL (male, 6.0±1.2mg/dL; female, 4.5
±1.0mg/dL), respectively. All of the baseline parameters, except
for the prevalence of renal dysfunction, were signiﬁcantly
different between men and women (Table 1).
We ﬁrst classiﬁed the subjects into three groups based on their
CAC scores: CAC group 1 (CAC score: 0, calcium absent); CAC
group 2 (CAC score: 1–299); and CAC group 3 (CAC score:
≥300). Based upon this classiﬁcation, a total of 3016 patients
(72.0%), 1024 patients (24.5%), and 148 patients (3.5%) were
categorized as CAC group 1, group 2, and group 3, respectively
(Supplemental Table 1, http://links.lww.com/MD/B638). Then,
we used linear trend tests to assess which parameters were
linearly associated with CAC scores. We found that, as the CAC
score increased, the following parameters increased signiﬁcantly:
age (P<0.001), BMI (P=0.047), proportion ofmales (P<0.001),
DM (P<0.001), hypertension (P<0.001), ever smokers (P<
0.001), renal dysfunction (P<0.001), degree of systolic blood
pressure (P<0.001), serum levels of BUN (P<0.001),
creatinine (P<0.001), fasting glucose (P<0.001), and UA
(P<0.001). Mean serum UA levels for each CAC group were
5.3±1.4mg/dL, 5.7±1.3mg/dL, and 5.9±1.3mg/dL in CAC
groups 1, 2 and 3, respectively. By contrast, serum levels of total
cholesterol
(P=0.004), LDL-cholesterol (P=0.006), and HDL cholesterol
(P=0.003) decreased signiﬁcantly as the CAC score increased
(Supplemental Table 1, http://links.lww.com/MD/B638). Addi-
tional, detailed ﬁndings between the groups are also provided in
Supplemental Table 1, http://links.lww.com/MD/B638.
Next, we explored which parameters were signiﬁcantly
associated with serum UA level. Male participants (B=1.567,
P<0.001) with hypertension (B=0.360, P<0.001), and a
history of smoking (B=0.668, P<0.001) were all signiﬁcantly
more likely to have elevated serum UA levels than were those
without these characteristics. With regard to continuous
variables, systolic blood pressure (B=0.014, P<0.001), BMI
(B=0.149, P<0.001), serum levels of CRP (B=0.933, P<
0.001), white blood cell count (B=0.160, P<0.001), hemoglo-
bin (B=0.418, P<0.001), fasting glucose (B=0.004, P<0.001),
total cholesterol (B=0.003, P<0.001), triglyceride (B=2.009,
P<0.001), and LDL-cholesterol (B=0.002, P=0.001) were all
signiﬁcantly positively associated with serum UA level. In
contrast, age (B=0.007, P=0.002), calculated eGFR (B=
1.888, P<0.001), and serum HDL-cholesterol (B=0.034, P<
0.001) were signiﬁcantly negatively associated with serum UA
level. Among these, age (B=0.008, P<0.001), male gender
(B=1.204, P<0.001), DM (B=0.216, P=0.003), hyperten-
sion (B=0.200, P<0.001), BMI (B=0.055, P<0.001), CRP
(B=0.406, P<0.001), hemoglobin (B=0.048, P=0.003), eGFR
(B=1.052, P<0.001), fasting glucose (B=0.004, P<0.001),
total cholesterol (B=0.004, P=0.016), triglyceride (B=0.367,
P=0.008), and HDL-cholesterol (B=0.008, P=0.001)
remained statistically signiﬁcant after adjustment for other
confounding variables (Table 2). As described in Table 3, the
CAC score groups showed a signiﬁcant positive association
with serum UA levels (Model 0, P<0.001). This statistical
signiﬁcance was retained throughout incremental adjustment
Table 1
Baseline characteristics of the participants.
All subjects N=4188 Males N=2559 (62.1%) Females N=1629 (38.9%) P-values for males vs. females
Age (years) 53.4±9.7 52.9±9.6 54.0±9.7 <0.001
Diabetes mellitus 304 (7.3) 213 (8.3) 91 (5.6) 0.001
Hypertension 856 (20.4) 567 (22.2) 289 (17.7) 0.001
Ever smoking 721 (17.2) 693 (26.7) 38 (2.3) <0.001
SBP (mm Hg) 126.9±16.9 128.8±15.7 123.8±18.1 <0.001
BMI (kg/m2) 24.1±3.2 24.8±2.9 22.9±3.2 <0.001
Laboratory parameters
C-reactive protein (mg/L) 1.8±5.8 2.0±7.1 1.4±2.9 <0.001
WBC count (103/mL) 5.7±1.7 5.9±1.7 5.3±1.5 <0.001
Hemoglobin (g/dL) 14.3±1.5 15.1±1.1 13.1±1.0 <0.001
Blood urea nitrogen (mg/dL) 14.1±3.5 14.4±3.5 13.5±3.4 <0.001
Creatinine (mg/dL) 0.9±0.2 1.0±0.2 0.7±0.2 <0.001
eGFR (mL/min/1.73 m2) 94.4±25.7 92.3±23.0 97.7±29.1 <0.001
Renal dysfunction 94 (2.2) 60 (2.3) 34 (2.1) 0.669
Glucose (mg/dL) 99.2±21.2 102.2±22.6 94.4±17.9 <0.001
Uric acid (mg/dL) 5.4±1.4 6.0±1.2 4.5±1.0 <0.001
Total cholesterol (mg/dL) 193.6±35.5 191.3±35.5 197.1±35.3 <0.001
Triglyceride (mg/dL) 120.0±78.2 136.9±87.8 93.3±49.6 <0.001
LDL-cholesterol (mg/dL) 120.7±33.4 118.7±33.5 123.9±33.0 <0.001
HDL- cholesterol (mg/dL) 49.1±12.3 45.5±10.6 54.8±12.8 <0.001
Results are expressed as mean±SD or number (%).
P-values by an independent t-test or Pearson’s chi-square test for comparisons between males and females.
BMI=body mass index, eGFR= estimated glomerular ﬁltration rate, HDL-cholesterol, high-density lipoprotein cholesterol, LDL-cholesterol= low-density lipoprotein cholesterol, SBP= systolic blood pressure,
WBC=white blood cell.
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multivariate-adjusted mean serum UA levels were estimated as
5.2±0.1mg/dL, 5.3±0.1mg/dL, and 5.6±0.2mg/dL in CAC
groups 1, 2, and 3, respectively (P for trend=0.001 and all
pairwise comparisons were signiﬁcant at P<0.05) (Fig. 2).
Finally, we investigated the interrelationship between CAC
groups and serum UA level in our various subgroups. The
differences in the number of patients, distribution of CAC
scores, and serum UA levels are provided in SupplementalTable 2
The univariate andmultivariate associations between serum uric acid l
B SE P
Age 0.007 0.002
Males 1.567 0.036
Diabetes mellitus 0.045 0.081
Hypertension 0.360 0.052
Ever smoking 0.668 0.055
SBP 0.014 0.001
BMI 0.149 0.006
Laboratory parameters
C-reactive protein
∗
0.933 0.080
WBC count 0.160 0.012
Hemoglobin 0.418 0.013
eGFR
∗ 1.888 0.190
Glucose 0.004 0.001
Total cholesterol 0.003 0.001
Triglyceride
∗
2.009 0.088
LDL-cholesterol 0.002 0.001
HDL- cholesterol 0.034 0.002
∗
Logarithmic transformation for analysis.
† P-values for univariate linear regression analysis between serum uric acid level and each baseline pa
‡ P-values for multivariate linear regression analysis between serum uric acid level and each baseline p
BMI=body mass index, eGFR= estimated glomerular ﬁltration rate, HDL-cholesterol, high-density lipopro
WBC=white blood cell.
4Table 2, http://links.lww.com/MD/B638. Across all subgroups,
the distributions of CAC scores were signiﬁcantly heterogeneous.
Advanced calciﬁed coronary lesions were more likely to be found
in older patients (median age ≥53 years), men, and those with
DM, hypertension, history of smoking, renal dysfunction, and
body mass index ≥25kg/m2 (all P-values<0.001). Similarly,
male patients with hypertension, smoking history, renal
dysfunction, or body mass index ≥25kg/m2 were more likely
to have higher serum UA levels compared to other patients (allevel and other baseline parameters from linear regression analysis.
-values† B SE P-values‡
0.002 0.008 0.002 <0.001
<0.001 1.204 0.050 <0.001
0.574 0.216 0.073 0.003
<0.001 0.200 0.045 <0.001
<0.001 0.017 0.047 0.713
<0.001 0.002 0.001 0.093
<0.001 0.055 0.006 <0.001
<0.001 0.406 0.068 <0.001
<0.001 0.007 0.011 0.536
<0.001 0.048 0.016 0.003
<0.001 1.052 0.154 <0.001
<0.001 0.004 0.001 <0.001
<0.001 0.004 0.002 0.016
<0.001 0.367 0.138 0.008
0.001 0.001 0.002 0.609
<0.001 0.008 0.002 0.001
rameter.
arameter.
tein cholesterol, LDL-cholesterol= low-density lipoprotein cholesterol, SBP= systolic blood pressure,
Table 3
The univariate and multivariate-adjusted associations between
serum uric acid levels and CAC groups from linear regression
analysis.
B SE P-values
Model 0 0.359 0.039 <0.001
Model 1 0.118 0.036 0.001
Model 2 0.107 0.036 0.003
Model 3 0.116 0.034 0.001
P-values for multivariate linear regression analysis between serum uric acid level and CAC groups.
Model 0, unadjusted.
Model 1, adjusted for age and sex.
Model 2, additionally adjusted for diabetes mellitus, hypertension, and ever smoking.
Model 3, additionally adjusted for SBP, BMI, the levels of CRP∗, WBC, hemoglobin, eGFR∗, glucose,
total cholesterol, triglyceride∗, HDL cholesterol, and LDL cholesterol.
∗Logarithmic transformation for analysis
BMI=body mass index, CAC= coronary artery calcium, CRP=C-reactive protein, eGFR= estimated
glomerular ﬁltration rate, HDL-cholesterol=high-density lipoprotein cholesterol, LDL-cholesterol=
low-density lipoprotein cholesterol, SBP= systolic blood pressure, WBC=white blood cell.
Kim et al. Medicine (2017) 96:14 www.md-journal.comP-values<0.001). We then analyzed whether the independent
associations between serum UA level and CAC scores were
retained in these subgroups (Table 4). There were signiﬁcant
differences among the subgroups. The positive, independent
association between serumUA level and CAC score was observed
exclusively in subjects with the following characteristics: above
the median age (≥53 years) (B=0.168, P<0.001); male gender
(B=0.153, P<0.001) (Supplemental Figs. 3 and 4, http://links.
lww.com/MD/B638); BMI<25kg/m2 (B=0.166, P<0.001); no
history of DM (B=0.125, P=0.001); hypertension (B=0.123,
P=0.002); history of smoking (B=0.105, P=0.007); or renal
dysfunction (B=0.102, P=0.003).4. Discussion
In this study, we found that serum UA levels were independently
associated with various baseline parameters (Table 2) inFigure 2. Themultivariate-adjusted estimatedmean levels of serum uric acid in
each CAC group. CAC = coronary artery calciﬁcation.
5relatively healthy subjects without overt coronary artery disease
or symptomatic urate deposition disease. These ﬁndings were
generally in agreement with previous studies that have been
conducted in Asian populations.[22–25] The negative association
between eGFR and serum UA was not surprising. It is well
recognized that a decline in the renal excretion of UA is the most
common cause of hyperuricemia. Hyperuricemia-induced renal
dysfunction was also observed in some studies.[26,27] However,
the causality between hyperuricemia and renal dysfunction needs
further veriﬁcation. The associations between serum UA levels,
age, and gender may be explained by the opposite uricosuric
effects of sex hormones on organic anion transporters.
Androgens promote the elevation of serum UA, while estrogens
inhibit it.[28] Therefore, as male age increased farther from the
peak androgen level at adolescence and early adulthood as in this
study, the more UA would be excreted. Similarly, this could
account for the direction of the gender differences with respect to
serum UA level. Furthermore, serum UA level was signiﬁcantly
associated with the main components of metabolic syndrome,
including hypertension, increasing BMI, and serum levels of
fasting glucose, triglycerides, and HDL-cholesterol. This rela-
tionship between UA and metabolic syndrome, or its compo-
nents, has been commonly observed in previous reports.[29–31] At
least one possible link between metabolic syndrome and
hyperuricemia is that high serum insulin levels reduce renal
UA excretion.[32] Furthermore, UA directly inhibited nitric oxide
(NO) release.[33] Conversely, inhibition of xanthine oxidase,
which is essential for UA formation, increased NO level in
rats.[34] NO is not only an integral part of metabolic
homeostasis,[35] but also of endothelial-dependent vasodilation.
In this context, a strong positive association between UA level
and hypertension can also be explained. Another potential
explanation linking these mechanisms includes UA-induced
inﬂammation with oxidative stress.[36] This mechanism could
support our ﬁndings of a positive association between CRP and
UA. Interestingly, DM has a signiﬁcant negative association with
serum UA level. That is, diabetic patients tend to have a
signiﬁcantly lower level of serum UA after adjusting for other
confounding variables. Although the exact underlying cause of
this relationship is not clear, this trend was also encountered in
previous studies.[22,37] One feasible explanation for this ﬁnding is
glucosuria-enhanced renal excretion of UA by inhibiting UA
reabsorption in the proximal tubules.[38]
Furthermore, we demonstrated that serum UA level was
independently associated with CAC score severity. We used CAC
scores≥300 for CAC group 3 (the highest category of CAC score)
in our study. The clinical signiﬁcance of this CAC score range has
been well validated in asymptomatic, low to intermediate-risk
individuals.[19] According to Greenland et al,[39] CAC scores
≥300 corresponded to a 15% 10-year coronary heart disease
(CHD) risk, which was associated with 3.9-fold higher odds of
CHD compared to a CAC score of 0. Similarly, CAC scores ≥300
were reported to be useful in identifying individuals at high risk
for CHD (>20% 10-year risk for CHD) among those with low to
intermediate risk for CHD (5–20% 10-year risk for CHD).[40,41]
It is still not clear if hyperuricemia is an independent predictor
for or has a causal role in advanced calciﬁed coronary
atherosclerosis. However, recent evidence suggests that UA
might play important roles in enhancing proinﬂammatory
pathways that are crucial to the progression of atherosclerotic
and metabolic lesions. This potential UA-induced vascular
inﬂammation was linked to arterial intimal calciﬁcation. The
mechanism is thought to involve inﬂammatory mediators
Table 4
The multivariate-adjusted associations between serum uric acid level and CAC groups in subgroups from linear regression analysis.
Subgroups Number of the patients (%) B SE P-values
Age ≥53 years (the median age) 2236 (53.4) 0.168 0.041 <0.001
Age <53 years (the median age) 1952 (46.6) 0.007 0.067 0.911
Male 2559 (61.1) 0.153 0.044 <0.001
Female 1629 (38.9) 0.050 0.056 0.373
With diabetes mellitus 304 (7.3) 0.054 0.102 0.599
Without diabetes mellitus 3884 (92.7) 0.125 0.037 0.001
With hypertension 856 (20.4) 0.087 0.069 0.210
Without hypertension 3332 (79.6) 0.123 0.040 0.002
With ever smoking 721 (17.2) 0.118 0.075 0.114
Without ever smoking 3467 (82.8) 0.105 0.039 0.007
With renal dysfunction 94 (2.2) 0.427 0.250 0.092
Without renal dysfunction 4094 (97.8) 0.102 0.035 0.003
BMI ≥25 kg/m2 1490 (35.6) 0.048 0.058 0.404
BMI <25 kg/m2 2698 (64.4) 0.166 0.043 <0.001
Results are expressed as number (%).
P-values for multivariate linear regression analysis between serum uric acid level and CAC groups within subgroups.
BMI=body mass index, CAC= coronary artery calcium.
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stimulating factor 1 (CSF-1), tumor necrosis factor-a (TNF-a),
and bone morphologic protein, as well as macrophage inﬁltra-
tion.[42,43] Collectively, we cautiously speculate that individuals
with elevated serum UA are at greater risk for developing
advanced atherosclerotic coronary calciﬁcation and future CHD
than are those with a lower level of serum UA.
Based upon the distribution of CAC scores by subgroup, we
next investigated the associations between serum UA levels and
CAC scores in speciﬁed subgroups. The association between
serum UA and CAC scores was found exclusively in individuals
who were male, relatively older, less overweight, and without a
history of DM, hypertension, smoking, or renal dysfunction
(Table 4). The positive associations between serum UA levels and
other surrogate markers of atherosclerosis have generally been
validated in previous cross-sectional studies.[44–46] However, the
results were not fully consistent depending on the measurement
method and subgroup categories. Chen et al[46] suggests that
there is a close association between serum UA level and
atherosclerotic lesions regardless of the underlying comorbid
conditions. In contrast, several other studies have been more
compatible with our results in that the relationship between
serum UA level and atherosclerotic disease depends on underly-
ing comorbidities. For instance, subclinical atherosclerosis
measured with the ankle-brachial index was associated with
serum UA levels in men, but not in women.[45] This male
predominance was also found in the relationship between UA
levels and carotid atherosclerosis.[29] In addition, in one study of
acute coronary syndrome, high serum UA levels were only
associated with the severity of coronary atherosclerosis in
patients without DM or hypertension.[15] The association
between serum UA levels and carotid atherosclerosis was evident
in patients with normal glucose metabolism, but not in those with
impaired glucose metabolism or DM.[47] Similarly, this relation-
ship was present in patients without metabolic syndrome, but not
in those with metabolic syndrome.[48] According to Shankar et
al,[44] peripheral arterial disease was signiﬁcantly associated with
serum UA level, but predominantly in nonsmoking and
nondiabetic patients. Therefore, this literature and our results
suggest that higher serum UA levels are more closely associated
with subclinical atherosclerosis in elderly patients with fewer6well-known cardiovascular risk factors than in those already
affected by advanced atherosclerotic diseases. That is, in a patient
with established atherosclerosis, a high serum UA level would
have little effect on atherosclerosis, despite its proinﬂammatory
potential.
The main strength of this study is that we recruited a relatively
large number of individuals of both genders without underlying
coronary artery disease or urate deposition disease. This design
allowed us to incorporate, exclude, or adjust various confound-
ing factors that potentially affected serum UA levels, including
DM, hypertension, renal dysfunction, obesity, or UA-related
medications. However, this study also has several limitations.
Due to the inherent limitations of cross-sectional studies, we
could not deﬁne any causal relationships among the serum UA
levels, various confounders, and CACs.
In conclusion, we found that the serum UA levels were
independently associated with the severity of coronary calciﬁca-
tion as measured byMDCT. Subgroup analysis revealed that this
relationship was exclusively observed in male individuals who
were relatively older, less overweight (body mass index<25kg/
m2), and without a history of DM, hypertension, smoking, or
renal dysfunction. Future prospective and interventional studies
are needed to clarify whether these associations are causal, or
merely coincidental.References
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